← Leaderboards
Thea Brennan-Krohn
Beth Israel Deaconess Medical Center
$2,347,967
Attributed
$2,347,967
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $484.4K · FY2018–24$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,347,967 · 3
By mechanism
R01$950,647 · 1
K08$916,070 · 1
R21$481,250 · 1
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- James E Kirby$9,890,264
Others in their field
Other Emerging Leaders on “Resistance”
- John Damon Chodera · Sloan-Kettering Inst Can Research$56,843,703
- Urs Ochsner · Crestone, Inc.$40,390,611
- Ryan Cirz · Revagenix, Inc.$40,209,479
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Michael Dignam · National Institute Of Allergy And Infectious Diseases$30,845,607
- Daniel Pevear · Venatorx Pharmaceuticals, Inc.$24,789,028
Research focus
ResistanceCollectionAntimicrobialNovel TherapeuticsPathogenResearch Project GrantsAntibioticsInfectionPharmaceutical PreparationsBacteriaGram-Negative BacteriaMulti-Drug ResistanceGrowthOrganismAntibiotic TherapyIn VivoInvestigationIn VitroClinical TrialsFrequenciesAntimicrobial SusceptibilityDesignClinical ResearchSynergism
Grant awards (10)
Susceptibility and resistance of multidrug-resistant gram-negative bacteria to novel beta-lactam/beta-lactamase inhibitor combinations$466,211
R01 · FY2024 · AI · contact PI
Susceptibility and resistance of multidrug-resistant gram-negative bacteria to novel beta-lactam/beta-lactamase inhibitor combinations$484,436
R01 · FY2023 · AI · contact PI
Identification of potentiators of antimicrobial activity against multidrug-resistant Burkholderia cepacia complex infections in cystic fibrosis$218,750
R21 · FY2022 · AI · contact PI
Antimicrobial Synergy for Carbapenem-Resistant Enterobacteriaceae$157,032
K08 · FY2022 · AI · contact PI
Identification of potentiators of antimicrobial activity against multidrug-resistant Burkholderia cepacia complex infections in cystic fibrosis$262,500
R21 · FY2021 · AI · contact PI
Antimicrobial Synergy for Carbapenem-Resistant Enterobacteriaceae$168,480
K08 · FY2021 · AI · contact PI
Antimicrobial Synergy for Carbapenem-Resistant Enterobacteriaceae$179,928
K08 · FY2020 · AI · contact PI
Antimicrobial Synergy for Carbapenem-Resistant Enterobacteriaceae - Administrative Supplement$27,878
K08 · FY2020 · AI · contact PI
Antimicrobial Synergy for Carbapenem-Resistant Enterobacteriaceae$191,376
K08 · FY2019 · AI · contact PI
Antimicrobial Synergy for Carbapenem-Resistant Enterobacteriaceae$191,376
K08 · FY2018 · AI · contact PI